DS
PHAS

David Shaw’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

David Shaw’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,796
Closed -$31K – 6170
2021
Q4 		$31K Sell
11,796
-66,751
-85% -$202K ﹤0.01% 5267
2021
Q3 		$244K Buy
78,547
+60,873
+344% +$203K ﹤0.01% 4477
2021
Q2 		$66K Buy
+17,674
New +$58.8K ﹤0.01% 4605

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
TCM
Towercrest Capital Management Newtown, Pennsylvania $717M AUM 15.39% 1-Year Est. Return
VPW
Vericrest Private Wealth Newtown, Pennsylvania $112M AUM

David Shaw's PHAS Position: Q1 2022 in Review

David Shaw sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 11,796 shares — an estimated $31K sold.

David Shaw first reported a position in PHAS in Q2 2021 and held it in 3 quarters. The position peaked at $244K in Q3 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

  • David Shaw reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • David Shaw sold 11,796 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $31K.
  • David Shaw first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • David Shaw's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $244K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.